VIR Form 4: Director Vicki Sato disposes 22,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $5.8362 per share, with individual sale prices ranging from $5.68 to $5.99. After the reported disposition, the filing shows the reporting person beneficially owned 1,232,391 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and includes an undertaking to provide detailed per-price sale breakdowns on request.

Insights

Financial Analyst

TL;DR: Routine director share sale under a pre-established 10b5-1 plan; disposal size appears modest relative to retained holdings.

The Form 4 documents a director-initiated disposal of 22,000 common shares executed pursuant to a Rule 10b5-1 plan adopted March 27, 2025. The weighted-average price reported is $5.8362, with execution prices between $5.68 and $5.99. The report confirms continuing beneficial ownership of 1,232,391 shares after the sale. Because the sale was executed under a 10b5-1 plan and the filer retains a substantial position, this appears to be a pre-arranged, non-discretionary transaction rather than an opportunistic insider sale.

Corporate Governance Expert

TL;DR: Disclosure follows standard SEC Form 4 conventions and cites a documented 10b5-1 plan; signatures and explanations are complete.

The filing identifies the reporting person as a director and specifies the Rule 10b5-1 trading plan adoption date, the weighted-average price range, and an offer to provide per-price sale details. The form is signed via attorney-in-fact and includes the required explanatory remarks. From a governance and disclosure perspective, the filing fulfills common transparency expectations for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S(1)		22,000	D	$5.8362(2)	1,232,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vir Biotechnology director Vicki L. Sato report on Form 4 (VIR)?

The Form 4 reports that Vicki L. Sato sold 22,000 shares of Vir Biotechnology common stock on 10/01/2025 under a Rule 10b5-1 trading plan.

At what price were the 22,000 shares sold according to the Form 4?

The filing reports a weighted-average price of $5.8362 per share, with individual sale prices ranging from $5.68 to $5.99.

How many Vir shares did the reporting person own after the sale?

Following the reported transaction, the Form 4 shows beneficial ownership of 1,232,391 shares.

Was the sale part of a pre-arranged trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2025.

Who signed the Form 4 and when?

The Form 4 was signed by Vanina de Verneuil, Attorney-In-Fact on 10/02/2025.